Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Clinical and Translational Medicine

Fig. 2

From: Clinical features of Sjögren’s syndrome patients with autoantibodies against interferons

Fig. 2

One SS patient contains partially neutralizing activity against interferon-α autoantibodies. PBMC were stimulated with interferon-α and interferon-γ in the absence and presence of serum. Phospho-STAT-1 monoclonal antibody followed by an anti-mouse-FITC secondary antibody was used for immunostaining. Each graph contains a red, blue, and green, line which represent cells unstimulated or stimulated by interferon-α, or interferon-γ, respectively. a HV control serum did not interfere with cell signaling by interferon-α and interferon-γ leading activation and phosphorylation of STAT-1. b In a thymoma patient serum, the presence of only anti-interferon-α autoantibodies block interferon-α binding therefore preventing phosphorylation. c SS patient #56, containing an intermediate level of serum anti-interferon-α autoantibodies can block some, but not all, interferon-α signaling activity leading to a partial block of phosphorylation

Back to article page